文献速递基础与转化研究新药、器械与细胞基因治疗研发

细胞毒性效应记忆T细胞亚群增强胰腺导管腺癌模型中的CAR-T疗效

A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma.
PubMed 文献 · Sci Transl Med · 2021-01-01

该研究聚焦人类NK细胞标记CD161定义的T细胞亚群,在小鼠中比较CD8+NK1.1+与CD8+NK1.1-细胞的基因表达和过继转移保护效果,并在人源HER2特异性CAR-T中比较CD8+CD161+与CD8+CD161-细胞的体外杀伤和体内抗肿瘤活性。结果显示CD8+CD161+ CAR-T细胞杀伤HER2+靶细胞更快更高效,在HER2+胰腺导管腺癌异种移植模型中抗肿瘤效果增强。

要点

  • CD8+CD161+ T细胞亚群具有增强的细胞毒性和记忆表型,颗粒酶和穿孔素表达上调。
  • CD8+CD161+ CAR-T细胞体外杀伤HER2+靶细胞更快更高效。
  • CD8+CD161+ CAR-T在HER2+胰腺导管腺癌异种移植模型中抗肿瘤效果增强。

核心结论

  • CD8+CD161+ T细胞亚群有潜力改善CAR-T细胞治疗实体瘤的疗效。

研究设计与样本

  • 研究在小鼠中比较CD8+NK1.1+与CD8+NK1.1- T细胞的基因表达谱和过继转移保护效果。
  • 研究比较人CD8+CD161+与CD8+CD161- T细胞及总PBMC的同种异体杀伤活性。
  • 研究比较转导HER2特异性CAR的PBMC、CD8+CD161-和CD8+CD161+ T细胞的体外杀伤和体内抗肿瘤效果。

主要发现

  • 小鼠CD8+NK1.1+ T细胞较CD8+NK1.1- T细胞显著上调颗粒酶、穿孔素、杀伤凝集素样受体和先天信号分子。
  • 来自既往暴露动物的CD8+NK1.1+细胞过继转移对黑色素瘤和流感感染提供更强保护和生存改善。
  • 新鲜分离的人CD8+CD161+ T细胞较CD8+CD161- T细胞或总PBMC显示增强的同种异体杀伤活性。
  • CD8+CD161+ CAR-T细胞体外杀伤HER2+靶细胞更快更高效。
  • CD8+CD161+ CAR-T细胞在HER2+胰腺导管腺癌异种移植模型中体内抗肿瘤效果增强,颗粒酶表达升高、耗竭标志物表达降低。

临床怎么用

  • 可考虑将CD8+CD161+ T细胞亚群作为CAR-T细胞治疗实体瘤的候选细胞群进行进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In humans, the natural killer (NK) cell marker CD161 identifies several subsets of T cells, including a polyclonal CD8 αβ T cell receptor-expressing subset with characteristic specificity for tissue-localized viruses. This subset also displays enhanced cytotoxic and memory phenotypes. Here, we characterized this unique T cell subset and determined its potential suitability for use in chimeric antigen receptor (CAR) T cell therapy. In mice, gene expression profiling among the CD161-equivalent CD8+ T cell populations (CD8+NK1.1+) revealed substantial up-regulation of granzymes, perforin, killer lectin-like receptors, and innate signaling molecules in comparison to CD8+NK1.1- T cells. Adoptive transfer of CD8+NK1.1+ cells from previously exposed animals offered substantially enhanced protection and improved survival against melanoma tumors and influenza infection compared to CD8+NK1.1- cells. Freshly isolated human CD8+CD61+ T cells exhibited heightened allogeneic killing activity in comparison to CD8+CD61- T cells or total peripheral blood mononuclear cells (PBMCs). To determine whether this subset might improve the antitumor efficacy of CAR T cell therapy against solid tumors, we compared bulk PBMCs, CD8+CD161-, and CD8+CD161+ T cells transduced with a human epidermal growth factor receptor-2 (HER2)-specific CAR construct. In vitro, CD8+CD161+ CAR-transduced T cells killed HER2+ targets faster and with greater efficiency. Similarly, these cells mediated enhanced in vivo antitumor efficacy in xenograft models of HER2+ pancreatic ductal adenocarcinoma, exhibiting elevated expression of granzymes and reduced expression of exhaustion markers. These data suggest that this T cell subset presents an opportunity to improve CAR T cell therapy for the treatment of solid tumors.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Konduri V, Joseph SK, Byrd TT, et al. A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma. Sci Transl Med. 2021. PMID: 33952672. doi:10.1126/scitranslmed.abc3196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。